Compare Incyte Corporation (INCY) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United States Natural Gas Fund — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while United States Natural Gas Fund trades at $11.01 (market cap $517.27M). The key difference: Incyte Corporation is far larger — about 44.2× United States Natural Gas Fund's market cap, and Incyte Corporation is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and United States Natural Gas Fund for 22 Days on average.
| INCY | UNG | |
|---|---|---|
Market Cap | $22.85B | $517.27M |
Volume | 1,927,029 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $129.93 | $16.90 |
52-Week Low | $83.80 | $9.63 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
UNG trades at $10.81, down 1.99% with a bullish technical signal from moving averages. The company reported $65.15M net income for 2024 despite zero revenue, with strong cash reserves of $593.54M and minimal debt. Recent news highlights natural gas price volatility driven by Middle East tensions and record US production levels.
The outlook remains mixed with technical strength but fundamental concerns around revenue generation. Key risks include commodity price exposure and geopolitical factors, while institutional sentiment appears cautiously optimistic given the clean balance sheet and operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
